The DOI matches its Crossref record.
Development of an antibody specific to major histocompatibility antigens detectable by flow cytometry after lung transplant is associated with bronchiolitis obliterans syndrome.
Abstract
BACKGROUND: Chronic allograft rejection manifested as bronchiolitis obliterans syndrome (BOS) is the leading cause of late death after lung transplantation. Although increasing evidence suggests an association between anti-human leukocyte antigens (HLA) antibodies and chronic rejection of kidney or heart allografts, the clinical significance of anti-HLA antibodies in lung recipients is less clear, especially in previously unsensitized recipients. The use of flow cytometry based panel reactive antibody (flow-PRA) provides a highly sensitive means to identify the development of de novo anti-HLA antibodies in lung recipients. METHODS: Flow-PRA testing was used to analyze the pre- and posttransplant sera in stable BOS free lung recipients who survived at least 6 months. Patients without prior sensitization as defined by a negative pretransplant flow-PRA were analyzed posttransplant for the presence of anti-HLA antibodies by flow-PRA. A proportional hazards model was used to determine the impact of anti-HLA antibody on BOS risk. RESULTS: Sera from 90 recipients at Duke University with negative pretransplant flow-PRA were tested by flow-PRA at various time points after transplant. Sera from 11% (10/90) of recipients were found to contain anti-HLA antibodies detectable by flow-PRA. Nine patients (90%) developed anti-HLA antibodies specific for donor antigens, and one patient developed anti-HLA class II antibodies, not specific to donor antigens. Among the nine patients with donor antigen specific antibodies, flow-PRA specificity analysis demonstrated eight were specific for class II antigens and one for class I antigens. In a multivariate model that controls for other BOS risk factors, a positive posttransplant flow-PRA was significantly associated with BOS grades 1,2, or 3 (hazard ratios [HR] 3.19; 95% confidence interval [CI]: 1.41-7.12, P=0.005) and BOS grade 2 or 3 (HR 4.08; 95% CI: 1.66-10.04, P=0.002). Four patients with de novo anti-HLA antibodies died during follow-up; all four had BOS. Among BOS patients, the presence of anti-HLA antibodies was associated with a significantly worse survival (P =0.05, log-rank test). CONCLUSIONS: Although uncommon, previously unsensitized lung transplant recipients can develop anti-HLA antibodies to donor class II antigens. The development of de novo anti-HLA antibodies significantly increases the risk for BOS, independent of other posttransplant events. Furthermore, de novo anti-HLA antibodies identify BOS patients with significantly worse survival. Additional studies are needed to determine if class II-directed anti-HLA antibodies contribute mechanistically to the chronic rejection process in lung recipients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Tait, B. D., Süsal, C., Gebel, H. M., Nickerson, P. W., Zachary, A. A., Claas, F. H. J., Reed, E. F., Bray, R. A., Campbell, P., Chapman, J. R., et al. (2013) · Transplantation · doi:10.1097/tp.0b013e31827a19cc · Cited by 787
Humoral Theory of Transplantation
Terasaki, P. I. (2003) · American Journal of Transplantation · doi:10.1034/j.1600-6143.2003.00135.x · Cited by 609
Meyer, K. C., Raghu, G., Verleden, G. M., Corris, P. A., Aurora, P., Wilson, K. C., Brozek, J., Glanville, A. R., & the ISHLT/ATS/ERS BOS Task Force Committee (2014) · European Respiratory Journal · doi:10.1183/09031936.00107514 · Cited by 555
National Conference to Assess Antibody-Mediated Rejection in Solid Organ Transplantation
Takemoto, S. K., Zeevi, A., Feng, S., Colvin, R. B., Jordan, S., Kobashigawa, J., Kupiec-Weglinski, J., Matas, A., Montgomery, R. A., Nickerson, P., et al. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2004.00500.x · Cited by 455
Burlingham, W. J., Love, R. B., Jankowska-Gan, E., Haynes, L. D., Xu, Q., Bobadilla, J. L., Meyer, K. C., Hayney, M. S., Braun, R. K., Greenspan, D. S., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci28031 · Cited by 398
Metadata
- Authors
- Palmer, S. M., Davis, R. D., Hadjiliadis, D., Hertz, M. I., Howell, D. N., Ward, F. E., Savik, K., & Reinsmoen, N. L.
- Venue
- Transplantation
- Published
- 2002-09
- Volume
- 74
- Issue
- 6
- Pages
- 799-804
- ISSN
- 0041-1337 (ISSN-L)
- OpenAlex
- W2126010472
- Cited by
- 195
- References
- 0
- FWCI
- 11.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Development of an antibody specific to major histocompatibility antigens detectable by flow cytometry after lung transplant is associated with bronchiolitis obliterans syndrome. https://app.cochat.ai/papers/10.1097/00007890-200209270-00011
- The paper
- Palmer, S. M., Davis, R. D., Hadjiliadis, D., Hertz, M. I., Howell, D. N., Ward, F. E., Savik, K., & Reinsmoen, N. L. (2002). Development of an antibody specific to major histocompatibility antigens detectable by flow cytometry after lung transplant is associated with bronchiolitis obliterans syndrome. Transplantation. https://doi.org/10.1097/00007890-200209270-00011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.